Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01460628 · ClinicalTrials.gov registry record · Phase 4

Effect of Nuvigil on Fatigue

A Phase 4 study of Menopause, sponsored by Massachusetts General Hospital.

Completed
Registry status
Phase 4
Development phase
25
Enrollment target
1
Study location

NCT01460628 is a Phase 4 study of Menopause that has completed, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01460628, a Phase 4 study of Menopause, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
Phase 4
Development phase
25 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if armodafinil improves quality of life and is an effective treatment of fatigue in symptomatic perimenopausal and postmenopausal women.

Conditions Studied

Interventions

  • DRUG Armodafinil

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2011-10
Est. Completion 2013-12
Phase Phase 4

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01460628

The ClinicalTrials.gov registry entry for NCT01460628 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 9,394-participant average among 54 other Menopause trials with a reported enrollment target (100% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Menopause appearing as the primary indexed condition, and to 1 intervention - of which Armodafinil is the first listed.

NCT01460628 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01460628 about?

NCT01460628 is a clinical study titled "Effect of Nuvigil on Fatigue". The purpose of this study is to determine if armodafinil improves quality of life and is an effective treatment of fatigue in symptomatic perimenopausal and postmenopausal women.

What is the current status of trial NCT01460628?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2011-10. Estimated completion is 2013-12.

What conditions does trial NCT01460628 study?

This clinical trial studies the following conditions: Menopause.

What interventions are being tested in trial NCT01460628?

The interventions under investigation include: Armodafinil (DRUG).

Who is sponsoring clinical trial NCT01460628?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01460628 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Menopause

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.